Tricalcium phosphate and osteogenin: a bioactive onlay bone graft substitute.
The disadvantages of autogenous bone grafts has prompted a search for a dependable onlay bone graft substitute. A combination of tricalcium phosphate, a resorbable ceramic, and osteogenin, an osteoinductive protein, was evaluated as an onlay bone graft substitute in a rabbit calvarial model. Twenty-eight tricalcium phosphate implants (15 mm diameter x 5 mm; pore size, 100-200 microns) were divided into experimental and control groups and placed on the frontal bone of 14 adult New Zealand White rabbits. In the experimental animals, 185 micrograms of osteogenin was added to each implant. In the control animals, the implants were placed untreated. Implants were harvested at intervals of 1, 3, and 6 months, and evaluated using hematoxylin and eosin histology, microradiography, and histomorphometric scanning electron microscope backscatter image analysis. At 1 month there was minimal bone ingrowth and little tricalcium phosphate resorption in both the osteogenin-treated and control implants. At 3 months, both the osteogenin-treated and control implants showed a modest increase in bone ingrowth (8.85 percent versus 5.87 percent) and decrease in tricalcium phosphate (32.86 percent versus 37.08 percent). At 6 months, however, the osteogenin-treated implants showed a statistically significant increase in bone ingrowth (22.33 percent versus 6.96 percent; p = 0.000) and decrease in tricalcium phosphate (27.25 percent versus 37.80 percent; p = 0.004) compared with the control implants. The bone within the control implants was mostly woven at 6 months, whereas the osteogenin-treated implants contained predominantly mature lamellar bone with well-differentiated marrow. All implants maintained their original volume at each time interval studied. The tricalcium phosphate/osteogenin composite, having the advantage of maintaining its volume and being replaced by new bone as the tricalcium phosphate resorbs, may be applicable clinically as an onlay bone graft substitute.
Breitbart
A S
AS
Institute of Reconstructive Plastic Surgery, New York University Medical Center, N.Y., USA.
Staffenberg
D A
DA
Thorne
C H
CH
Glat
P M
PM
Cunningham
N S
NS
Reddi
A H
AH
Ricci
J
J
Steiner
G
G
D000818:Animals; D001672:Biocompatible Materials; D055398:Bone Morphogenetic Protein 3; D019485:Bone Morphogenetic Proteins; D018786:Bone Substitutes; D002130:Calcium Phosphates; D005624:Frontal Bone / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery; D006133:Growth Substances; D008297:Male; D008852:Microradiography; D008855:Microscopy, Electron, Scanning; D011506:Proteins; D011817:Rabbits; D051381:Rats
D001672:Biocompatible Materials; C525759:Bmp3 protein, rat; D055398:Bone Morphogenetic Protein 3; D019485:Bone Morphogenetic Proteins; D018786:Bone Substitutes; D002130:Calcium Phosphates; D006133:Growth Substances; D011506:Proteins; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; C485838:calcium phosphate, monobasic, anhydrous; C020243:calcium phosphate; C485829:calcium phosphate, dibasic, anhydrous